A randomized, double-masked, parallel-group, comparative study to evaluate the clinical efficacy and safety of 1% azithromycin–0.1% dexamethasone combination compared to 1% azithromycin alone, dexamethasone 0.1% alone, and vehicle in the treatment of subjects with blepharitis
Kamran Hosseini,1 Richard L Lindstrom,2,3 Gary Foulks,4 Kelly K Nichols5 1InSite Vision, Alameda, CA, 2Minnesota Eye Consultants, 3Department of Ophthalmology and Visual Neurosciences, University of Minnesota Medical School, Minneapolis, MN, 4Department of Ophthalmology and Vision Science, School o...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a01d9c0fb50c4a5685986f2d35951ed0 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:a01d9c0fb50c4a5685986f2d35951ed0 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:a01d9c0fb50c4a5685986f2d35951ed02021-12-02T07:56:40ZA randomized, double-masked, parallel-group, comparative study to evaluate the clinical efficacy and safety of 1% azithromycin–0.1% dexamethasone combination compared to 1% azithromycin alone, dexamethasone 0.1% alone, and vehicle in the treatment of subjects with blepharitis1177-5483https://doaj.org/article/a01d9c0fb50c4a5685986f2d35951ed02016-08-01T00:00:00Zhttps://www.dovepress.com/a-randomized-double-masked-parallel-group-comparative-study-to-evaluat-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Kamran Hosseini,1 Richard L Lindstrom,2,3 Gary Foulks,4 Kelly K Nichols5 1InSite Vision, Alameda, CA, 2Minnesota Eye Consultants, 3Department of Ophthalmology and Visual Neurosciences, University of Minnesota Medical School, Minneapolis, MN, 4Department of Ophthalmology and Vision Science, School of Medicine, University of Louisville, Louisville, KY, 5School of Optometry, University of Alabama at Birmingham, Birmingham, AL, USA Purpose: To evaluate the clinical efficacy and safety of a 1% azithromycin–0.1% dexamethasone combination in DuraSite (“combination”) compared to 0.1% dexamethasone in DuraSite, 1% azithromycin in DuraSite, and vehicle in the treatment of subjects with blepharitis.Materials and methods: This was a Phase III, double-masked, vehicle-controlled, four-arm study in which 907 subjects with blepharitis were randomized to combination (n=305), 0.1% dexamethasone (n=298), 1% azithromycin (n=155), or vehicle (n=149). Ten study visits were scheduled: screening visit, days 1 and 4 (dosing phase) and 15, and months 1–6 (follow-up phase). On day 1, subjects applied one drop of the study drug to the eyelid of the inflamed eye(s) twice daily, and continued with twice-daily dosing for 14 days. After completing 14 days of dosing, subjects were followed for 6 months for efficacy and safety.Results: A total of 57 subjects (6.3%) had complete clinical resolution at day 15: 25 (8.2%), 17 (5.7%), 8 (5.2%), and 7 (4.7%) subjects in the combination-, 0.1% dexamethasone-, 1% azithromycin-, and vehicle-treatment groups, respectively. The combination was superior to 1% azithromycin and vehicle alone, but not to 0.1% dexamethasone alone. Mean composite (total) clinical sign and symptom scores improved in all four treatment groups during the posttreatment evaluation phase for the intent-to-treat population, but outcomes were superior when a drop containing 0.1% dexamethasone was utilized. Clinical response was noted as early as day 4, and persisted as long as 6 months. Most adverse events were considered mild in severity and not related to the study drug.Conclusion: A higher percentage of subjects in the combination group achieved complete clinical resolution of the signs and symptoms of blepharitis at day 15 than with 1% azithromycin and vehicle, but outcomes were similar to treatment with 0.1% dexamethasone alone. The combination was well tolerated. Keywords: blepharitis, dexamethasone, azithromycin, eyelid inflammationHosseini KLindstrom RLFoulks GNichols KKDove Medical PressarticleblepharitisdexamethasoneazithromycinDuraSiteOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2016, Iss Issue 1, Pp 1495-1503 (2016) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
blepharitis dexamethasone azithromycin DuraSite Ophthalmology RE1-994 |
| spellingShingle |
blepharitis dexamethasone azithromycin DuraSite Ophthalmology RE1-994 Hosseini K Lindstrom RL Foulks G Nichols KK A randomized, double-masked, parallel-group, comparative study to evaluate the clinical efficacy and safety of 1% azithromycin–0.1% dexamethasone combination compared to 1% azithromycin alone, dexamethasone 0.1% alone, and vehicle in the treatment of subjects with blepharitis |
| description |
Kamran Hosseini,1 Richard L Lindstrom,2,3 Gary Foulks,4 Kelly K Nichols5 1InSite Vision, Alameda, CA, 2Minnesota Eye Consultants, 3Department of Ophthalmology and Visual Neurosciences, University of Minnesota Medical School, Minneapolis, MN, 4Department of Ophthalmology and Vision Science, School of Medicine, University of Louisville, Louisville, KY, 5School of Optometry, University of Alabama at Birmingham, Birmingham, AL, USA Purpose: To evaluate the clinical efficacy and safety of a 1% azithromycin–0.1% dexamethasone combination in DuraSite (“combination”) compared to 0.1% dexamethasone in DuraSite, 1% azithromycin in DuraSite, and vehicle in the treatment of subjects with blepharitis.Materials and methods: This was a Phase III, double-masked, vehicle-controlled, four-arm study in which 907 subjects with blepharitis were randomized to combination (n=305), 0.1% dexamethasone (n=298), 1% azithromycin (n=155), or vehicle (n=149). Ten study visits were scheduled: screening visit, days 1 and 4 (dosing phase) and 15, and months 1–6 (follow-up phase). On day 1, subjects applied one drop of the study drug to the eyelid of the inflamed eye(s) twice daily, and continued with twice-daily dosing for 14 days. After completing 14 days of dosing, subjects were followed for 6 months for efficacy and safety.Results: A total of 57 subjects (6.3%) had complete clinical resolution at day 15: 25 (8.2%), 17 (5.7%), 8 (5.2%), and 7 (4.7%) subjects in the combination-, 0.1% dexamethasone-, 1% azithromycin-, and vehicle-treatment groups, respectively. The combination was superior to 1% azithromycin and vehicle alone, but not to 0.1% dexamethasone alone. Mean composite (total) clinical sign and symptom scores improved in all four treatment groups during the posttreatment evaluation phase for the intent-to-treat population, but outcomes were superior when a drop containing 0.1% dexamethasone was utilized. Clinical response was noted as early as day 4, and persisted as long as 6 months. Most adverse events were considered mild in severity and not related to the study drug.Conclusion: A higher percentage of subjects in the combination group achieved complete clinical resolution of the signs and symptoms of blepharitis at day 15 than with 1% azithromycin and vehicle, but outcomes were similar to treatment with 0.1% dexamethasone alone. The combination was well tolerated. Keywords: blepharitis, dexamethasone, azithromycin, eyelid inflammation |
| format |
article |
| author |
Hosseini K Lindstrom RL Foulks G Nichols KK |
| author_facet |
Hosseini K Lindstrom RL Foulks G Nichols KK |
| author_sort |
Hosseini K |
| title |
A randomized, double-masked, parallel-group, comparative study to evaluate the clinical efficacy and safety of 1% azithromycin–0.1% dexamethasone combination compared to 1% azithromycin alone, dexamethasone 0.1% alone, and vehicle in the treatment of subjects with blepharitis |
| title_short |
A randomized, double-masked, parallel-group, comparative study to evaluate the clinical efficacy and safety of 1% azithromycin–0.1% dexamethasone combination compared to 1% azithromycin alone, dexamethasone 0.1% alone, and vehicle in the treatment of subjects with blepharitis |
| title_full |
A randomized, double-masked, parallel-group, comparative study to evaluate the clinical efficacy and safety of 1% azithromycin–0.1% dexamethasone combination compared to 1% azithromycin alone, dexamethasone 0.1% alone, and vehicle in the treatment of subjects with blepharitis |
| title_fullStr |
A randomized, double-masked, parallel-group, comparative study to evaluate the clinical efficacy and safety of 1% azithromycin–0.1% dexamethasone combination compared to 1% azithromycin alone, dexamethasone 0.1% alone, and vehicle in the treatment of subjects with blepharitis |
| title_full_unstemmed |
A randomized, double-masked, parallel-group, comparative study to evaluate the clinical efficacy and safety of 1% azithromycin–0.1% dexamethasone combination compared to 1% azithromycin alone, dexamethasone 0.1% alone, and vehicle in the treatment of subjects with blepharitis |
| title_sort |
randomized, double-masked, parallel-group, comparative study to evaluate the clinical efficacy and safety of 1% azithromycin–0.1% dexamethasone combination compared to 1% azithromycin alone, dexamethasone 0.1% alone, and vehicle in the treatment of subjects with blepharitis |
| publisher |
Dove Medical Press |
| publishDate |
2016 |
| url |
https://doaj.org/article/a01d9c0fb50c4a5685986f2d35951ed0 |
| work_keys_str_mv |
AT hosseinik arandomizeddoublemaskedparallelgroupcomparativestudytoevaluatetheclinicalefficacyandsafetyof1azithromycinndash01dexamethasonecombinationcomparedto1azithromycinalonedexamethasone01aloneandvehicleinthetreatmentofsubjectswithblepharitis AT lindstromrl arandomizeddoublemaskedparallelgroupcomparativestudytoevaluatetheclinicalefficacyandsafetyof1azithromycinndash01dexamethasonecombinationcomparedto1azithromycinalonedexamethasone01aloneandvehicleinthetreatmentofsubjectswithblepharitis AT foulksg arandomizeddoublemaskedparallelgroupcomparativestudytoevaluatetheclinicalefficacyandsafetyof1azithromycinndash01dexamethasonecombinationcomparedto1azithromycinalonedexamethasone01aloneandvehicleinthetreatmentofsubjectswithblepharitis AT nicholskk arandomizeddoublemaskedparallelgroupcomparativestudytoevaluatetheclinicalefficacyandsafetyof1azithromycinndash01dexamethasonecombinationcomparedto1azithromycinalonedexamethasone01aloneandvehicleinthetreatmentofsubjectswithblepharitis AT hosseinik randomizeddoublemaskedparallelgroupcomparativestudytoevaluatetheclinicalefficacyandsafetyof1azithromycinndash01dexamethasonecombinationcomparedto1azithromycinalonedexamethasone01aloneandvehicleinthetreatmentofsubjectswithblepharitis AT lindstromrl randomizeddoublemaskedparallelgroupcomparativestudytoevaluatetheclinicalefficacyandsafetyof1azithromycinndash01dexamethasonecombinationcomparedto1azithromycinalonedexamethasone01aloneandvehicleinthetreatmentofsubjectswithblepharitis AT foulksg randomizeddoublemaskedparallelgroupcomparativestudytoevaluatetheclinicalefficacyandsafetyof1azithromycinndash01dexamethasonecombinationcomparedto1azithromycinalonedexamethasone01aloneandvehicleinthetreatmentofsubjectswithblepharitis AT nicholskk randomizeddoublemaskedparallelgroupcomparativestudytoevaluatetheclinicalefficacyandsafetyof1azithromycinndash01dexamethasonecombinationcomparedto1azithromycinalonedexamethasone01aloneandvehicleinthetreatmentofsubjectswithblepharitis |
| _version_ |
1718399116078219264 |